Methods and compositions for neuroprotection
AssigneeDisarm Therapeutics, Inc.
InventorsLiza Leventhal, Thomas Engber, Raul Eduardo Krauss, Rajesh Devraj, Robert Owen Hughes, Todd Bosanac, Sudhir Agrawal, Marco A. Passini
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for treating neurodegeneration and neurodegenerative diseases associated with axonal degeneration. Neurodegeneration and neurodegenerative diseases associated with axonal degeneration are treated with therapies comprising SARM1 inhibitors such as SARM1 antisense oligonucleotides.
Claims18
An antisense oligonucleotide comprising a sequence having at least 95% identity to a sequence selected from a group consisting of SEQ ID NO:
- 4-10, 12-14, 18-21, 23-26, and 38.
An antisense oligonucleotide comprising a sequence having at least 95% identity to a sequence selected from a group consisting of SEQ ID NO:
- 3-21, 23-26, 38 and 39, wherein the antisense oligonucleotide comprises one or more modifications, the one or more modifications comprise methylphosphonothioate internucleotide linkages, phosphorothioate internucleotide linkages, methylphosphonate internucleotide linkages, phosphoramidate internucleotide linkages, a 3′ end cap, a 3′ hair-pin loop structure, or a combination thereof and the antisense oligonucleotide comprises internucleotide linkages of the pattern RSRORSRORSDSDSDSDSDSDSDSDSDSDSRORSRORS, wherein RS is an RNA (2′-MOE) phosphorothioate bond, RO is an RNA (2′-MOE) phosphodiester bond and DS is a DNA phosophorothioate bond.
An antisense oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:
- 2410-2412, wherein the antisense oligonucleotide comprises internucleotide linkages of the pattern RSRORSRORSDSDSDSDSDSDSDSDSDSDSRORSRORS, wherein RS is an RNA (2′-MOE) phosphorothioate bond, RO is an RNA (2′-MOE) phosphodiester bond and DS is a DNA phosophorothioate bond.
Dependencies are inferred from the claim text.